Select Your Region
Americas
Europe
Africa
Global
A study to evaluate the long-term safety and tolerability of faricimab administered in patients previously enrolled in Roche-sponsored studies
An open-label, multicenter extension study to evaluate the long-term safety and tolerability of faricimab administered in patients previously enrolled in studies sponsored by F. Hoffmann-La Roche Ltd
Eye Disorder Age-Related Macular Degeneration
Basic Details
Both
Mixed
No
Sponsor
F. Hoffmann-La Roche Ltd (Switzerland), Genentech Inc (USA)
Study Identifier
YR42837
Who can participate?
Patients who were previously enrolled in the mainland of China and completed any of Roche-sponsored faricimab parent trials
What does the study involve?
Participants will be placed in a single treatment group:
Participants will receive faricimab 6 mg injections into the study eye at a variable interval depending on the condition of their eye. Frequency of injections will be determined by the study doctor, usually varying between every 4 weeks and every 16 weeks.
Participants will only be required to attend the clinic according to the study doctor’s discretion, but the interval between visits should be no more than 4 months and no less than 21 days.
What are the possible benefits and risks of participating?
Your health may or may not improve in this study, but the information that is learned may help other people who have a similar medical condition in the future.
You may have side effects from the drugs or procedures used in this study. Side effects can be mild to severe and even life threatening, and they can vary from person to person. There may be a risk in exposing an unborn child to the study drug, and all risks are not known at this time. Women and men must take precautions to avoid exposing an unborn child to the study drug.
Where is the study run from?
Shanghai General Hospital (China)
When is the study starting and how long is it expected to run for?
August 2020 to August 2025
Who is funding the study?
F. Hoffmann-La Roche Ltd (Switzerland)
Genentech Inc (USA)
The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.
The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.
Results Disclaimer
What you can do next
To find this study again later, copy and save the study number:
{{ctId}}
Interested in more than one study? Log in to your ForPatients account to bookmark studies and get updates.
To see if this study is a good fit, talk to your doctor or nurse you trust.
Together, you can look at the For Medical Professional tab and look into your medical history.
Some medical centers in this study offer a contact line. Click "Find participating medical centers" in the map below.
For the latest version of this information please go to www.forpatients.roche.com